Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Bioequivalence of Drugs: Drugs with Multiple Indications01:09

Bioequivalence of Drugs: Drugs with Multiple Indications

94
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each...
94
Ethical Issues01:27

Ethical Issues

1.8K
Nurses are essential in patient care, upholding the ethical principles of their profession and effectively navigating ethical dilemmas. Neglecting ethical issues can lead to inadequate patient care, compromised therapeutic relationships, and moral distress among healthcare workers.
Ethical Concerns in Healthcare:
1.8K
Dosage Regimen: Individualization01:24

Dosage Regimen: Individualization

110
Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...
110
Bioequivalence Data: Statistical Interpretation01:16

Bioequivalence Data: Statistical Interpretation

127
Body:The statistical interpretation of bioequivalence data is a significant aspect of pharmaceutical research. Bioequivalence refers to the absence of any significant difference in the rate and extent to which the active ingredient in pharmaceutical products becomes available at the site of drug action when administered at the same molar dose under similar conditions. This helps determine if different drug products have similar absorption rates, ensuring their interchangeability.Statistical...
127
Bioequivalence: Overview01:16

Bioequivalence: Overview

1.6K
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
1.6K
Patient-centered Care01:13

Patient-centered Care

2.8K
Patient-centered care involves delivering care beyond inpatient hospitalization. Reflective practice can enhance a patient-centered approach. Reflective practice is a process of reasoning that considers all aspects of the present situation, including practicalities, learning from personal practice, and consideration of patient needs. Patients appreciate care decisions made while considering their input. Involving the patient in their care provides the patient with a sense of contribution rather...
2.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Price of National Pharmaceutical Pricing in the EU: A Proposal for "Common Procurement".

Applied health economics and health policy·2026
Same author

Timely, Cheap, or Risk-Free? The Effect of Regulation on the Price and Availability of New Drugs.

Pharmacy (Basel, Switzerland)·2024
Same author

The impact of conventional cost-effectiveness analysis on pricing dynamics in the market of new medicines: a proposed countervailing approach.

Expert review of pharmacoeconomics & outcomes research·2023
Same author

Less is more: an ecological and economic point of view on appropriate use of lab testing for COVID-19 patients.

Bioanalysis·2021
Same author

A reply to "Who would benefit from average value-based pricing?"

Health economics·2021
Same author

Beyond price: the effects of non-financial barriers on access to drugs and health outcomes.

The European journal of health economics : HEPAC : health economics in prevention and care·2021

Related Experiment Video

Updated: Dec 18, 2025

Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence
07:54

Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence

Published on: October 25, 2011

19.0K

Which valued-based price when patients are heterogeneous?

Rosella Levaggi1, Paolo Pertile2

  • 1Department of Economics and Management, University of Brescia, Brescia, Italy.

Health Economics
|June 16, 2020
PubMed
Summary
This summary is machine-generated.

This study models healthcare regulation, finding average value-based prices ensure both static and dynamic efficiency for medical innovations, despite higher costs. Heterogeneity in patient response increases the cost of efficiency.

Keywords:
personalized medicineprecision medicinestatic and dynamic efficiencyvalue-based prices

More Related Videos

Using Visual and Narrative Methods to Achieve Fair Process in Clinical Care
14:32

Using Visual and Narrative Methods to Achieve Fair Process in Clinical Care

Published on: February 16, 2011

24.2K
Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers
11:34

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers

Published on: December 5, 2017

13.0K

Related Experiment Videos

Last Updated: Dec 18, 2025

Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence
07:54

Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence

Published on: October 25, 2011

19.0K
Using Visual and Narrative Methods to Achieve Fair Process in Clinical Care
14:32

Using Visual and Narrative Methods to Achieve Fair Process in Clinical Care

Published on: February 16, 2011

24.2K
Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers
11:34

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers

Published on: December 5, 2017

13.0K

Area of Science:

  • Health economics
  • Pharmaceutical policy
  • Innovation economics

Background:

  • Regulation of medical innovations impacts healthcare spending and patient access.
  • Heterogeneity in patient response to treatments complicates optimal reimbursement strategies.
  • Balancing static (current efficiency) and dynamic (future innovation) efficiency is a key challenge in healthcare policy.

Purpose of the Study:

  • To model and compare the static and dynamic efficiency of alternative reimbursement regulation regimes for medical innovations.
  • To analyze the impact of heterogeneous patient responses on the efficiency of different pricing strategies.
  • To identify optimal pricing mechanisms that consider both firm behavior and patient outcomes.

Main Methods:

  • Development of a simple economic model.
  • Analysis of static and dynamic efficiency under different reimbursement regimes.
  • Incorporation of rational, profit-maximizing firm behavior.
  • Consideration of heterogeneous patient responses to medical treatments.

Main Results:

  • Average value-based prices are necessary for both static and dynamic efficiency when accounting for firm behavior.
  • These optimal prices lead to increased expenditure and reduced consumer surplus.
  • Marginal value-based prices may be preferred by payers if patient responses are homogeneous, ignoring dynamic efficiency.
  • A refinement of average value-based prices can alter these outcomes.
  • The cost of achieving static and dynamic efficiency rises with patient response heterogeneity.

Conclusions:

  • Achieving both static and dynamic efficiency in medical innovation reimbursement is complex and costly, especially with heterogeneous patient responses.
  • Average value-based pricing, while ensuring efficiency, presents a trade-off with healthcare expenditure and consumer surplus.
  • Policy design must carefully consider the degree of patient heterogeneity when setting reimbursement strategies for new medical treatments.